Adial Pharmaceuticals (Adial Pharmaceuticals) Total Assets : $4.74 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Adial Pharmaceuticals Total Assets?

Adial Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $4.74 Mil.

During the past 12 months, Adial Pharmaceuticals's average Total Assets Growth Rate was 10.30% per year. During the past 3 years, the average Total Assets Growth Rate was 20.60% per year. During the past 5 years, the average Total Assets Growth Rate was 20.00% per year.

During the past 9 years, Adial Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 300.20%. The lowest was 19.40%. And the median was 82.90%.

Total Assets is connected with ROA %. Adial Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was -202.00%. Total Assets is also linked to Revenue through Asset Turnover. Adial Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Adial Pharmaceuticals Total Assets Historical Data

The historical data trend for Adial Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adial Pharmaceuticals Total Assets Chart

Adial Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

7.68

5.49

7.48

5.73

4.74

Adial Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															5.73	3.90	3.78	2.87	4.74

Adial Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Adial Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	4.084	+	0.653
	=	4.74

Adial Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	4.084	+	0.653
	=	4.74

Adial Pharmaceuticals (NAS:ADIL) Total Assets Explanation

Total Assets is connected with ROA %.

Adial Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-7.68	/	( (2.867	+	4.737)	/ 2 )
	=	-7.68	/	3.802
	=	-202.00 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Adial Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (2.867	+	4.737)	/ 2 )
=	0	/	3.802
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Adial Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Adial Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Adial Pharmaceuticals (Adial Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adial Pharmaceuticals Inc (NAS:ADIL) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1180 Seminole Trail, Suite 495, Charlottesville, VA, USA, 22901

Website

https://www.adialpharma.com

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.

Executives

Kevin Schuyler	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Stilley William B. Iii	director, 10 percent owner, officer: Chief Executive Officer	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Newman James W. Jr.	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Cary J Claiborne	director	3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Bankole A. Johnson	director, 10 percent owner	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Jack W Reich	director	C/O COLLATERAL THERAPEUTICS, 11622 EL CAMINO REAL, SAN DIEGO CA 92130
Tony Goodman	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
J. Kermit Anderson	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Joseph Truluck	officer: COO and CFO	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Robertson H. Gilliland	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
En Fidecomiso De Mi Vida 11/23/2010 Trust	10 percent owner	11024 GAITHER FARM ROAD, ELLICOTT CITY MD 21042